Please login to the form below

Not currently logged in
Email:
Password:

Further Tylenol recall for J&J

Johnson & Johnson's McNeil Consumer Healthcare division has announced the voluntary recall of one product lot of Tylenol extra strength caplets in the US following reports of a 'mouldy odour'

Johnson & Johnson's McNeil Consumer Healthcare division has announced the voluntary recall of one product lot of Tylenol extra strength caplets in the US following reports of a 'mouldy odour'.

Around 60,000 bottles are affected, with the unusual smell linked to trace amounts of a chemical known as 2,4,6-tribromoanisole (TBA), a by-product of a chemical preservative sometimes applied to wood often used in the construction of pallets on which materials are transported.

Earlier this month, J&J's Ortho-McNeil-Janssen subsidiary voluntarily recalled one unit each of schizophrenia drugs Risperdal and risperidone for a similar reason.

J&J said: "This voluntary action is being taken as a precaution and the risk of serious adverse medical events is remote. TBA can generate an offensive odour and has been associated with temporary and non-serious gastrointestinal symptoms."

It is recommend that consumers who have purchased the product from the lot number (ABA619 ) stop using the drug and contact McNeil Consumer Healthcare for further information.

The latest announcement follows several Tylenol recalls by McNeil Consumer Healthcare since May 2010.

29th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...